<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>24(3)</volume><submitter>Golderman V</submitter><pubmed_abstract>Diabetic encephalopathy (DE) is an inflammation-associated diabetes mellitus (DM) complication. Inflammation and coagulation are linked and are both potentially modulated by inhibiting the thrombin cellular protease-activated receptor 1 (PAR1). Our aim was to study whether coagulation pathway modulation affects DE. Diabetic C57BL/6 mice were treated with PARIN5, a novel PAR1 modulator. Behavioral changes in the open field and novel object recognition tests, serum neurofilament (NfL) levels and thrombin activity in central and peripheral nervous system tissue (CNS and PNS, respectively), brain mRNA expression of tumor necrosis factor α (TNF-α), Factor X (FX), prothrombin, and PAR1 were assessed. Subtle behavioral changes were detected in diabetic mice. These were accompanied by an increase </pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>2021</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9917200</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy.</pubmed_title><pmcid>PMC9917200</pmcid><pubmed_authors>Sher I</pubmed_authors><pubmed_authors>Golderman V</pubmed_authors><pubmed_authors>Dori A</pubmed_authors><pubmed_authors>Goldberg Z</pubmed_authors><pubmed_authors>Gofrit SG</pubmed_authors><pubmed_authors>Chapman J</pubmed_authors><pubmed_authors>Rotenstreich Y</pubmed_authors><pubmed_authors>Shavit-Stein E</pubmed_authors><pubmed_authors>Maggio N</pubmed_authors></additional><is_claimable>false</is_claimable><name>PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy.</name><description>Diabetic encephalopathy (DE) is an inflammation-associated diabetes mellitus (DM) complication. Inflammation and coagulation are linked and are both potentially modulated by inhibiting the thrombin cellular protease-activated receptor 1 (PAR1). Our aim was to study whether coagulation pathway modulation affects DE. Diabetic C57BL/6 mice were treated with PARIN5, a novel PAR1 modulator. Behavioral changes in the open field and novel object recognition tests, serum neurofilament (NfL) levels and thrombin activity in central and peripheral nervous system tissue (CNS and PNS, respectively), brain mRNA expression of tumor necrosis factor α (TNF-α), Factor X (FX), prothrombin, and PAR1 were assessed. Subtle behavioral changes were detected in diabetic mice. These were accompanied by an increase </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-08-16T03:06:20.314Z</modification><creation>2025-04-06T07:58:06.571Z</creation></dates><accession>S-EPMC9917200</accession><cross_references><pubmed>36768341</pubmed><doi>10.3390/ijms24032021</doi></cross_references></HashMap>